Contact Us

Follow

Innovations that improve & extend patients’ lives

"The technology being developed at Pulse has the potential to quickly, safely, painlessly and effectively remove skin lesions, including cancers, for both clinical and cosmetic purposes. It is tremendously exciting. We will be hugely proud to bring it to the public."

Bob Duggan

Overview

Pulse Biosciences is a bioelectric medicine company, developing innovations that improve and extend patients’ lives. Pulse’s groundbreaking Nano-Pulse Stimulation (NPS) technology is used to treat a variety of conditions that currently have no established optimal solution. The first planned commercial product, the CellFX System, uses NPS technology to address a range of dermatologic conditions.

NPS technology is based on nanosecond pulses of high-amplitude electrical energy that non-thermally clear targeted cells while sparing adjacent non-cellular tissue. It is a precise, drug‐free tissue treatment that directly affects cell membranes and intracellular structures to stimulate unique behavior in the cells. It initiates a regulated cell death process with minimal inflammatory response, thus improving healing outcomes. It supports the replacement of treated tissue cells with healthy tissue cells.

In cancerous lesions, NPS has been shown to induce immunogenic cell death (ICD), exposing the antigens of the treated cells to the immune system. A result is the generation of cytotoxic T cells and the mounting of an adaptive immune response targeted against those cells.

Pulse Biosciences is investigating a variety of applications for its technology, including immuno‐oncology, dermatology, and veterinary medicine.

Technology

Nano-Pulse Stimulation (NPS™) is a proprietary technology that delivers nanosecond pulses of high-amplitude electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue.

These ultrafast electrical energy pulses have pulse durations from billionths up to a millionth of a second.

When applied to the targeted tissue, NPS energy pulses enter cells and alter the function of the internal cellular organelles, including the mitochondria and endoplasmic reticulum, without disrupting extracellular tissue. This leads to regulated cell death (RCD), a process exhibited by cells in the human body when they undergo stress and are unable to restore cellular homeostasis.

The CellFX System delivers pulses that directly affect the internal organelles of targeted cells but have no functional effect on non-cellular tissue, such as collagen (a proteinaceous tissue that forms the structural foundation of the skin). In short, it delivers a unique cell-focused effect to the internal structures of treated cells while preserving surrounding non-cellular tissue. This combination may lead to highly differentiated treatment applications.

The CellFX™ System is planned as a commercial product using NPS technology to create a non-toxic and non-thermal biophysical disruption of targeted cells, using tunable speed and amplitude of NPS pulses.

“Along with a team of qualified scientists, we have studied Pulse Biosciences’ core technology, the strength of leadership and management, patent portfolio, breadth of engineering and research talent, as well as our perceived long‐term sense of the robust potential of NPS technology in healthcare. We are impressed by what we have seen and with the experience, ability, and enthusiasm of the Pulse Biosciences team. We have previously worked closely with several members of the Pulse Biosciences management team, including Darrin Uecker, President, and CEO, and Dave Danitz and Edison Manuel, engineering and operations executives. Each of them were critical to our previous success at Computer Motion, Inc. (now part of Intuitive Surgical, Inc.) in launching computer-assisted robotics in the field of human surgery. We look forward to working with the Pulse Biosciences team on this important technology that we believe can impact healthcare in a meaningful and sustainable manner for the significant betterment of all,” Mr. Duggan and Dr. Zanganeh in a joint statement.

Key Dates

Presentation of clinical studies data to clear skin lesions at ASDS annual meeting

17 Oct 2019

Go to link

Promising non-thermal treatment for skin conditions

18 Sep 2019

Go to link

Pulse Biosciences CellFX™ system to be given podium presentation at major Aesthetic Procedures conference

06 Aug 2019

Go to link

Publication of dose-response study using PulseX system

02 Aug 2019

Go to link

Research program explores energy for lesion treatment

14 May 2019

Go to link

Media

Decrease in the number of active acne lesions on the back 3 months after a single nano-pulse stimulation treatment —Mark S. Nestor, MD, PhD

25 Oct 2019

Go to link

This first human study of the treatment describes the use of nanosecond pulsed electric fields (nsPEF) on the skin

18 Sep 2019

Go to link

Nano-pulse stimulation represents novel technology for delivering cellular specific therapy that is being investigated for its potential to treat both benign and malignant dermatological lesions

14 May 2019

Go to link

"This is an incredibly exciting technology...There’s a whole world, both cosmetic and clinical, including skin cancer that’s going to be looked at continually as we go forward."

Mark S. Nestor

MD, PhD

Key Dates

Presentation of clinical studies data to clear skin lesions at ASDS annual meeting

17 Oct 2019

Promising non-thermal treatment for skin conditions

18 Sep 2019

Pulse Biosciences CellFX™ system to be given podium presentation at major Aesthetic Procedures conference

06 Aug 2019

Publication of dose-response study using PulseX system

02 Aug 2019

Research program explores energy for lesion treatment

14 May 2019

Media

Decrease in the number of active acne lesions on the back 3 months after a single nano-pulse stimulation treatment —Mark S. Nestor, MD, PhD

25 Oct 2019

This first human study of the treatment describes the use of nanosecond pulsed electric fields (nsPEF) on the skin

18 Sep 2019

Nano-pulse stimulation represents novel technology for delivering cellular specific therapy that is being investigated for its potential to treat both benign and malignant dermatological lesions

14 May 2019